TOP > 外国特許検索 > LUNG-CANCER-PROGRESS EVALUATION METHOD, LUNG-CANCER-PROGRESS EVALUATION DEVICE, LUNG-CANCER-PROGRESS EVALUATION PROGRAM, LUNG-CANCER-PROGRESS EVALUATION SYSTEM, AND INFORMATION COMMUNICATION TERMINAL DEVICE

LUNG-CANCER-PROGRESS EVALUATION METHOD, LUNG-CANCER-PROGRESS EVALUATION DEVICE, LUNG-CANCER-PROGRESS EVALUATION PROGRAM, LUNG-CANCER-PROGRESS EVALUATION SYSTEM, AND INFORMATION COMMUNICATION TERMINAL DEVICE NEW

外国特許コード F190009676
整理番号 S2018-0590-N0
掲載日 2019年1月22日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP030043
国際公開番号 WO 2018079029
国際出願日 平成29年8月23日(2017.8.23)
国際公開日 平成30年5月3日(2018.5.3)
優先権データ
  • 特願2016-209657 (2016.10.26) JP
発明の名称 (英語) LUNG-CANCER-PROGRESS EVALUATION METHOD, LUNG-CANCER-PROGRESS EVALUATION DEVICE, LUNG-CANCER-PROGRESS EVALUATION PROGRAM, LUNG-CANCER-PROGRESS EVALUATION SYSTEM, AND INFORMATION COMMUNICATION TERMINAL DEVICE NEW
発明の概要(英語) [Problem] To provide an evaluation method that makes it possible to determine the progress of lung cancer from variation in cytokine concentration data over time and an evaluation device, program, evaluation system, and information communication terminal device used in the method.
[Solution] Concentration data for at least two types of cytokines acquired from a sample collected from a subject for evaluation is acquired over time (that is, the concentration data is sampled intermittently or acquired continuously using a sensor). Examining the variation over time of the cytokine concentration data obtained in this way makes it possible to evaluate the progress of lung cancer in the subject for evaluation.
従来技術、競合技術の概要(英語) BACKGROUND ART
Cancer patient death due to cancer metastasis interrupt 9, the cancer is cancer metastasis to regulator the regulator is called.However, the current clinical MRI or CT used in the form of a device or a diagnosis based on information, such as PET is based on the function information of the diagnostic instrument, a diameter of 1 cm or less can be accurately detected lymph node metastasis does not have a level of accuracy.
Cancer metastasis not occur randomly, to the lung and breast cancer, colon cancer is a liver or the like, the degree of directionality.To control the selectivity of this organ is a group of cytokines called chemokines.Cell chemokine and a major migration effect, which cells (lymphocytes) or proceed to which organ, a chemokine receptor is strictly controlled by the (non-patent document 1).In addition, such as Scopus search engine and review the document, after the year 1977, up to 21 million cancer and cytokine related to the edited and published journal articles in the English, and the onset of cancer between the type and concentration of a cytokine, or is not associated with any of the thought.And further, concentrations of cytokines in a body fluid such as a cancer diagnosis data are used has been proposed (for example, JP-1-4).
In addition, an increase of the concentration with the progress of the stage of the investigation was performed in the prior art for cytokines, Bodo et al., in Non-Patent Document 2, the concentration of the IL-6 increases along with the stated.Also, Liu et al., Non-Patent Document 3 (MIC-1) in the concentration of the cytokine-1 increase with the stage is stated.However, any type of 1 and focusing attention on only the cytokine concentration, a plurality of levels of relationship is not reported.On the other hand, lowers the concentration of the stage with the progress of the investigation was performed in the prior art for cytokines, non-patent document 4 in Fig. 2 Matanic et al. in, (NSCLC) patients with non-small cell lung cancer, in the progression of the disease was observed a slight reduction of doses described as the, based on statistical analysis of the significance is not shown.Also, in non-patent document 5 in Fig. 1 Guadagni et al., the level of IL-6 NSCLC comparison of the stage1-3 appear to decrease in the stage 4 data is shown, based on statistical analysis of the significance is not shown.That is, the stage with the progress of the concentration of cytokines that might be present, medical evidence and is not shown.
It should be noted that, not the evaluation of cancer by cytokines, two or more amino acids in body fluids 2 in the concentration of pancreatic cancer using the data and evaluating the proposals have been made, in the present invention is related to an analysis technique is employed for evaluation, (Patent Document 5) and the reference.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SHINSHU UNIVERSITY
  • 発明者(英語)
  • YAMAGUCHI Masaki
  • KOIZUMI Tomonori
国際特許分類(IPC)
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close